drugset / Trial / NCT04453813
Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
Phase 3
Recruiting
226 enrolled
Sun Yat-sen University
Affiliated Cancer Hospital & Institute of Guangzhou Medical University · collabFifth Affiliated Hospital, Sun Yat-Sen University · collabWuzhou Red Cross Hospital · collabYuebei People's Hospital · collabZhongshan People's Hospital, Guangdong, China · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that concurrent and adjuvant PD-1 treatment added to concurrent chemo-radiotherapy could further decrease the rate of disease progression and improve the survival outcome of patients with unresectable locally recurrent nasopharyngeal carcinoma compared with those treated with concurrent chemo-radiotherapy alone.
Timeline
- Start
- 2020-07-03
- Primary completion
- 2025-07
- Completion
- 2027-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |
| Comparator | Cisplatin | Other / unclassified | 100 mg/m2 | Intravenous |